Indoco Grows By Almost A Sixth In Q2
As Company’s First-Half Operating Profit Sees 89.2% Jump
India’s Indoco has reported double-digit sales growth, as well as a jump in operating profit and EBITDA for its financial second quarter ended 30 September 2021. The company has seen consistent growth on the back on domestic and international launches.
You may also be interested in...
Margins Slow For Indoco Despite Sustained Revenue Growth
Indoco’s revenue rise and profit dip in the third quarter indicates the effects of rising input costs are starting to bite.
Indoco Sees Domestic And International Growth
Indoco has seen double-digit growth in domestic and international markets in the first quarter of financial year 2022. Headquartered in Mumbai, Indoco has reported overall growth of almost 43% and an increase of 124.6% in its operating profit in Q1 FY22.
Indoco’s US Business Grows After Azopt Rival Launch
India’s Indoco saw its international business grow after Teva launched the Indoco-manufactured and developed first US generic version of Novartis’ Azopt (brinzolamide) 1% solution. Though the company saw muted domestic growth, it aims to bolster its overall performance by launching 20 products a year by 2023.